Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer
|
|
- Clifton Nicholson
- 6 years ago
- Views:
Transcription
1 Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer Jin Gu Lee, MD, Byoung Chul Cho, MD, Mi Kyung Bae, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, and Kyung Young Chung, MD Departments of Thoracic and Cardiovascular Surgery and Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea Background. Although the survival benefit of adjuvant chemotherapy for nonsmall-cell lung cancer has been proved, 50% to 86% of patients received all planned cycles of chemotherapy. A thoracoscopic procedure may enable more effective administration of adjuvant chemotherapy than a thoracotomy. However, a well-balanced comparison is lacking. Methods. Patients who underwent pulmonary resection and received platinum-based double adjuvant chemotherapy for nonsmall-cell lung cancer were identified from a prospective database. A propensity score-matched analysis was performed to obtain a well-balanced comparison between thoracoscopy and thoracotomy to determine compliance of adjuvant chemotherapy. Results. Seventy-four patients (group A) with thoracoscopy and 278 patients with thoracotomy received adjuvant chemotherapy. Through 1:1 matching, 74 patients (group B) were selected from the thoracotomy group. A higher percentage of group A received four cycles of the planned adjuvant chemotherapy (95.9% versus 82.4%, p 0.015). There was a trend toward better compliance in group A with four cycles of adjuvant chemotherapy without reduced dose (83.8% versus 73.0%, p 0.162), and four cycles of adjuvant chemotherapy without delayed or reduced dose (70.3% versus 62.2%, p 0.385). Conclusions. Thoracoscopy showed better compliance with adjuvant chemotherapy after pulmonary resection for nonsmall-cell lung cancer. (Ann Thorac Surg 2011;91:344 9) 2011 by The Society of Thoracic Surgeons Although survival benefit of adjuvant chemotherapy after complete resection for stage IB and IIIA nonsmall-lung cancer (NSCLC) has been proved [1-5], only 50% to 87% of patients receive all planned cycles of chemotherapy [4-6]. This poor compliance with adjuvant chemotherapy is one of obstacles to improve the survival of patients with NSCLC who need adjuvant chemotherapy. Thus, efforts that facilitate the delivery of chemotherapy may improve survival of patients with lung cancer. Thoracoscopic pulmonary resection is a currently accepted approach for patients with NSCLC and is suggested to be associated with several advantages compared with conventional thoracotomy, including shorter length of hospitalization and chest tube duration, decreased postoperative pain, improved preservation of pulmonary function, and fewer overall complications [7-9]. One of the suggested advantages is to enable more effective administration of adjuvant chemotherapy to patients who need adjuvant chemotherapy [9, 10]. However, a well-balanced comparison of the two procedures related to compliance of chemotherapy is lacking in the literature. We designed this study according to the following hypothesis: thoracoscopic lobectomy is associated with Accepted for publication Sept 15, Address correspondence to Dr Chung, 250 Seongsanno, Seodaemun-Gu, CPO Box 8044, Seoul , South Korea; kychu@yumc.yonsei.ac.kr. superior compliance with adjuvant chemotherapy compared with conventional thoracotomy in a well balanced comparison. Patients and Methods Patients We retrospectively assessed our prospective data cohort of 1416 patients with NSCLC who underwent pulmonary resection at our institution between January 2000 and December Patients who underwent lobectomy or bi-lobectomy and received platinum based doublet adjuvant chemotherapy were included in this study. Patients who received preoperative therapy were excluded. Ultimately, a total of 352 patients were evaluated. Of these, 74 patients (group A) underwent thoracoscopic lobectomy and 278 patients underwent thoracotomy. Through propensity score matching, 74 patients (group B) were selected in the thoracotomy group to compare with group A. Pathology staging was based on the 1997 TNM classification system [11]. Blood samples for hematologic cell count had been obtained on admission to the unit before adjuvant chemotherapy. A pain score was measured at the first visit after operation according to the numerical pain intensity scale (scale 0 to 10). The prescription rate for pain medications was analyzed at 2011 by The Society of Thoracic Surgeons /$36.00 Published by Elsevier Inc doi: /j.athoracsur
2 Ann Thorac Surg LEE ET AL 2011;91:344 9 CHEMOTHERAPY COMPLIANCE AFTER THORACOSCOPY the first visit after operation. Delayed administration of adjuvant chemotherapy was defined as more than 1 week delay or readmission for chemotherapy. The Institutional Review Board of Yonsei University College of Medicine approved this retrospective study. The need for individual consent of patients whose records were evaluated was waived because individuals were not identified within the study. Operative Technique During the study period, thoracoscopic lobectomy was performed from In the beginning period, early stage lung cancer was indicated for thoracoscopic resection, and the indication was extended to patients who need adjuvant treatment after pulmonary resection. In 2009, more than half of the resections for lung cancer were performed by thoracoscopy. Thoracoscopic lobectomy was performed with a 3-cm to 5-cm utility incision at the anterior axillary line at the fourth or fifth intercostal space, using endoscopic instruments without rib spreading and two or three ports for camera, stapler insertion, and assistant. The operation was performed entirely with thoracoscopic visualization. The hilar structures were individually ligated by endovascular staplers, and the mediastinal nodal dissection was performed. Thoracotomy lobectomy was performed through a posterolateral thoracotomy incision. Staplers were routinely used for the transection of vessels and the completion of the fissures. In all patients, an ipsilateral mediastinal lymph node dissection was performed. Adjuvant Chemotherapy Postoperative adjuvant chemotherapy was recommended for all stage II to IIIB lung cancer. For IB patients, the choice of postoperative therapy was determined by the availability of adjuvant therapy protocols and physician preference. Most patients received cisplatin (80 mg/m 2 ) based chemotherapy; the regimens of chemotherapy were not different between the groups. Decisions about dose reduction or dose delay were made by the treating medical oncologist at the time of the scheduled dose using objective criteria (white cell count, absolute neutrophil count, serum creatinine, gastrointestinal symptoms, and neurologic symptoms) and subjective criteria (performance status). Radiation therapy was given sequentially after chemotherapy to selected patients. Statistical Analysis The association between variables was analyzed by either 2 test or t test. A propensity score-matched analysis was performed to get a well-balanced comparison. Propensity scores were generated for all patients eligible to undergo either thoracoscopy or thoracotomy. Thoracoscopy versus thoracotomy was the treatment indicator (dependent variable), and the covariates were age, sex, forced expiratory volume in 1 second (FEV 1 [%]), T stage, N stage, procedure (lobectomy or bilobectomy), histology, and smoking history. 345 The nearest neighbor matching method was used without replacement. A p value of less than 0.05 was considered significant. Data were analyzed using SPSS for Windows (Statistical Package for Social Science; SPSS, Chicago, IL) and matching macro. Results Patient Characteristics Patients who underwent thoracotomy showed a significantly higher incidence of male sex, smoking history, squamous histology, aggressive procedure (bilobectomy versus lobectomy), and advanced stage (T, N, stage) compared with patients who underwent thoracoscopy (group A; Table 1). Through propensity score matching, 74 patients (group B) were selected in the thoracotomy group, and they showed similar characteristics (age, sex, smoking history, pulmonary function, procedure, T, N, stage, histology) as group A (Table 2). Compliance With Adjuvant Chemotherapy A higher percentage of group A received four cycles of the planned adjuvant chemotherapy (95.9% versus 82.4%, p 0.015). There was a trend toward better compliance in group A with four cycles of adjuvant chemotherapy without reduced dose (83.8% versus 73.0%, p 0.162), and four cycles of adjuvant chemotherapy without delayed or reduced dose (70.3% versus 62.2%, p 0.385). There was no significant difference in time to the initiation of chemotherapy after operation ( versus , p 0.447; Table 3). Postoperative Pain, Performance Status, and Hematologic Cell Count Patients in group A showed a lower pain score at the first visit after operation ( versus , p 0.008). The prescription rate for analgesics was also lower in group A (52.7% versus 80.8%, p 0.001). There was a trend toward better performance status in group A before the start of adjuvant chemotherapy. In terms of hematologic cells, patients in group A showed a significantly higher white cell count ( versus , p 0.012) and absolute neutrophil count ( versus , p 0.010) before adjuvant treatment. There was no difference in platelet count between the groups (Table 4). Thoracoscopy and Thoracotomy showed a shorter length of stay in the intensive care unit ( versus , p 0.004) and chest tube duration ( versus , p 0.045), and decreased blood loss during the operation ( cc versus cc, p 0.020) compared with group B. also showed a trend toward shorter lengths of hospitalization ( versus , p 0.054). Operation time and the incidence of complication were not different between the groups (Table 5). There was no operative mortality in either group. GENERAL THORACIC
3 346 LEE ET AL Ann Thorac Surg CHEMOTHERAPY COMPLIANCE AFTER THORACOSCOPY 2011;91:344 9 Table 1. Clinical and Surgical Characteristics Before Matching Variables Thoracoscopy (n 74) Thoracotomy (n 278) Age, mean (range) 60.0 (35 76) 60.9 (32 80) Sex Male 41 (55.4) 215 (77.3) Female 33 (44.6) 63 (22.7) Smoking history Yes 35 (47.3) 170 (61.2) No 39 (52.7) 108 (38.8) ECOG functional class 0 69 (93.2) 190 (68.3) 1 5 (6.8) 83 (29.9) 2 5 (1.8) FEV FEV 1 % Procedure Lobectomy 71 (95.9) 227 (81.7) Bilobectomy 3 (4.1) 51 (18.3) T stage (20.3) 39 (14.0) 2 55 (74.3) 173 (62.2) 3 1 (1.4) 44 (15.8) 4 3 (4.1) 22 (7.9) N stage 0 42 (56.8) 81 (29.1) 1 12 (16.2) 102 (36.7) 2 20 (27.0) 87 (31.3) 3 0 (0.0) 8 (2.9) Pathology stage IB 39 (52.7) 51 (18.3) IIA 5 (6.8) 21 (7.6) IIB 8 (10.8) 85 (30.6) IIIA 20 (27.0) 92 (33.1) IIIB 2 (2.7) 29 (10.4) Histology Adenocarcinoma 56 (75.7) 127 (45.7) Squamous 11 (14.9) 116 (41.7) Other 7 (9.5) 35 (12.6%) FEV 1 forced expi- ECOG Eastern Cooperative Oncology Group; ratory volume in 1 second. Patients Who Were Intolerant of Adjuvant Chemotherapy Patients who were intolerant of adjuvant chemotherapy were analyzed. Three patients could not complete four cycles of adjuvant chemotherapy in group A. The reason was poor tolerance in 1 patient, grade 3 dyspnea in 1 patient, and recurrence in 1 patient. Thirteen patients could not complete four cycles of adjuvant chemotherapy in group B. The reason was death after pneumonia in 2 patients, pneumonia in 2 patients, poor tolerance in 3 patients, hematologic suppression in 3 patients, recurrence in 2 patients, and refusal in 1 patient. Comment Patients who underwent thoracoscopy showed better compliance rates with adjuvant chemotherapy compared with patients who underwent conventional thoracotomy. Table 2. Clinical and Surgical Characteristics After Propensity Score Matching Variables (n 74) (n 74) Age, mean (range) 60.0 (35 76) 58.3 (35 74) Sex Male 41 (55.4) 44 (59.5) Female 33 (44.6) 30 (40.5) Smoking history Yes 35 (47.3) 36 (48.6) No 39 (52.7) 38 (51.4) ECOG functional class (93.2) 69 (93.2) 1 5 (6.8) 4 (5.4) 2 1 (1.4) FEV FEV 1 % Procedure Lobectomy 71 (95.9) 72 (97.3) Bilobectomy 3 (4.1) 2 (2.7) T stage (20.3) 11 (14.9) 2 55 (74.3) 54 (73.0) 3 1 (1.4) 1 (1.4) 4 3 (4.1) 8 (10.8) N stage (56.8) 47 (63.5) 1 12 (16.2) 12 (16.2) 2 20 (27.0) 15 (20.3) 3 0 (0.0) 0 (0.0) Pathology stage IB 39 (52.7) 39 (52.7) IIA 5 (6.8) 3 (4.1) IIB 8 (10.8) 9 (12.2) IIIA 20 (27.0) 15 (20.3) IIIB 2 (2.7) 8 (10.8) Histology Adenocarcinoma 56 (75.7) 54 (73.0) Squamous 11 (14.9) 15 (20.3) Other 7 (9.5) 5 (6.8) Radiotherapy Yes 10 (13.5) 13 (17.6) No 64 (86.5) 61 (82.4) White blood cell count, ,000 a Absolute neutrophil count a Platelet count, 1,000 a a Before operation. FEV 1 forced expi- ECOG Eastern Cooperative Oncology Group; ratory volume in 1 second.
4 Ann Thorac Surg LEE ET AL 2011;91:344 9 CHEMOTHERAPY COMPLIANCE AFTER THORACOSCOPY Table 3. Adjuvant Chemotherapy Compliance After Lobectomy by Surgical Approach Compliance Time to start of chemotherapy, Patients with chemotherapy 1 cycle 1 (1.4) 3 (4.1) 2 cycles 1 (1.4) 4 (5.4) 3 cycles 1 (1.4) 6 (8.1) 4 cycles 71 (95.9) 61 (82.4) Patients with 4 cycles 71 (95.9) 61 (82.4) Patients with 4 cycles, 62 (83.8) 54 (73.0) full dose Patients with 4 cycles, full dose, no delay 52 (70.3) 46 (62.2) Postoperative pain score, analgesics prescription rate, and performance status were better for thoracoscopy patients. White cell count and absolute neutrophil count were higher in thoracoscopy patients before adjuvant chemotherapy. Based on these results, we can predict better compliance with adjuvant chemotherapy for the thoracoscopy group, and it seems to be associated with lower postoperative pain, better performance status, and better preserved hematologic function before adjuvant chemotherapy. Thoracoscopic major lung resection for early stage lung cancer has now gained wide acceptance, although some surgeons remain skeptical about its oncologic safety, long-term benefit, and cost effectiveness. The Table 4. Postoperative pain, Functional Status, and Hematologic Cell Count by Surgical Approach Variable Pain score at first visit Prescription for pain at first visit None 35 (47.3) 14 (19.2) Nonopioid 9 (12.2) 12 (16.4) Opioid 30 (40.5) 47 (64.4) ECOG score before chemotherapy 0 18 (24.3) 10 (13.5) 1 52 (70.3) 54 (73.0) 2 4 (5.4) 10 (13.5) White blood cell count, ,000 a Absolute neutrophil count a Platelet count, 1,000 a a Before adjuvant chemotherapy. ECOG Eastern Cooperative Oncology Group. Table 5. Postoperative Course After Lobectomy Complication 347 Operation time, minutes Intensive care unit stay, Hospitalization, Chest tube duration, Blood loss during operation, cc Complications Total 18 (24.3) 16 (21.6) Respiratory failure 0 1 Middle lobe torsion 0 1 Prolonged air leak Atrial fibrillation 3 4 Pneumonia 3 5 Vocal cord palsy 1 0 Chylothorax 1 0 Pneumothorax 1 1 Abdominal ileus 1 1 Hematoma 1 0 suggested advantages of thoracoscopic resection compared with conventional thoracotomy were shorter length of hospitalization and chest tube duration, decreased postoperative pain, improved preservation of pulmonary function, and fewer overall complications [7-9]. Our results also indicated that thoracoscopic resection was associated with shorter intensive care unit stay and chest tube duration, and decreased blood loss during the operation, and these patients tended to have a shorter hospitalization. Recently, studies have suggested that thoracoscopic lung resection facilitates the delivery of adjuvant chemotherapy, resulting in a higher compliance rate, fewer delays, and reduced dose of chemotherapy [9, 10]. Although the survival benefit of adjuvant chemotherapy has been proven for patients with NSCLC after pulmonary resection, only 50% to 87% of patients received all of the planned cycles of chemotherapy [4-6]. This study focuses on this compliance with adjuvant chemotherapy because the effort to increase the compliance could prolong the survival of patients who need adjuvant chemotherapy after pulmonary resection for NSCLC. The compliance with chemotherapy can be influenced by several factors such as age, sex, and extent of resection [6]. Through propensity score matching, we obtained a well-balanced comparison of the groups, and this comparison showed that thoracoscopic pulmonary resection is associated with better compliance with adjuvant chemotherapy compared with conventional thoracotomy. A possible explanation of this better compliance is associated with a preserved hematologic system after a less traumatic procedure. Major surgery can affect nu- GENERAL THORACIC
5 348 LEE ET AL Ann Thorac Surg CHEMOTHERAPY COMPLIANCE AFTER THORACOSCOPY 2011;91:344 9 merous immune factors, which may have an impact on postoperative infection and compliance with immunosuppressive chemotherapy. Patients who have to receive adjuvant chemotherapy have suffered from hematologic suppression, and they need adequate immune function to complete planned adjuvant chemotherapy. Most studies thus far on postoperative immunosuppression have been based on open and laparoscopic abdominal surgery [12]. There is growing evidence to suggest that the body s immune function is better preserved after thoracoscopy compared with thoracotomy, as documented by the release of proinflammatory and antiinflammatory cytokines, immune-modulatory cytokines, circulating T cells, natural killer cells, lymphocyte function, and quicker cell recovery [12-14]. Our data showed that the white cell count and absolute neutrophil cell count before adjuvant chemotherapy (26.9 and 28.1 after operation, respectively) were higher in the thoracoscopy group, suggesting that hematologic function is more quickly recovered or better preserved after thoracoscopy compared with thoracotomy. Most patients who were intolerant of adjuvant chemotherapy in our study had had pneumonia and hematologic suppression. The findings from these patients also support this explanation. A second possible explanation seems to be associated with less postoperative pain and better performance status. Less postoperative pain, better performance status, and preserved pulmonary function are already wellknown advantages after thoracoscopic resection [7-9]. Our data also showed less postoperative pain, a lower prescription rate for pain medications, and better performance status after thoracoscopic resection. These advantages could also be associated with better compliance with adjuvant chemotherapy. Compared with previously reported studies about adjuvant chemotherapy compliance after thoracoscopy and thoracotomy, the present study has analyzed adjuvant chemotherapy compliance through a well-balanced comparison with propensity score matching. The present study also suggests that better compliance after thoracoscopic pulmonary resection could be related to preserved hematologic function resulting from less traumatic procedures, aside from less postoperative pain and better performance status. In summary, our results indicate that thoracoscopic pulmonary resection for NSCLC showed better compliance with adjuvant chemotherapy, and this better compliance was correlated with less postoperative pain, a better performance status, and better hematologic function. Based on these results, we can apply the thoracoscopic procedure not only to patients with early stage NSCLC but also to patients who need adjuvant chemotherapy, if it does not disturb oncologic principles. References 1. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010;28: Winton TL, Livingstan R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine (VNR) and cisplatin (CIS) in completely resected stage Ib and II non small cell lung cancer (NSCLC). Intergroup JBR10. N Engl J Med 2005;352: Strauss GM, Hernden J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage Ib non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633 [abstract]. J Clin Oncol 2004;22: 621s. 4. Strauss GM, Hernden JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups. J Clin Oncol 2008;26: Douillard J, Rosell R, Delena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7: Alam N, Shepherd FA, Winton T, et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and Intergroup Trial JBR.10 and a review of the literature. Lung Cancer 2005;47: Villamizar NR, Darrabie MD, Burfeind WR, et al. Thoracoscopic lobectomy is associated with lower morbidity compared with thoracotomy. J Thorac Cardiovasc Surg 2009;138: Paul S, Altorki NK, Sheng S, et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. J Thorac Cardiovasc Surg 2010;139: Nicastri DG, Wisnivesky JP, Litle VR, et al. Thoracoscopic lobectomy: report on safety, discharge independence, pain, and chemotherapy tolerance. J Thorac Cardiovasc Surg 2008;135: Petersen RP, Pham D, Burfeind WR, et al. Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. Ann Thorac Surg 2007;83: Mountain CF. Revision of the international system for staging lung cancer. Chest 1997;111: Ng CS, Whelan RL, Lacy AM, et al. Is minimal access surgery for cancer associated with immunologic benefits? World J Surg 2005;29: Ng CS, Lee TW, Wan S, et al. Thoracotomy is associated with significantly more profound suppression in lymphocytes and natural killer cells than video assisted thoracic surgery following major lung resections for cancer. J Invest Surg 2005;18: Leaver HA, Craig SR, Yap PL, et al. Lymphocyte responses following open and minimally invasive thoracic surgery. Eur J Clin Invest 2000;30: INVITED COMMENTARY This study by Lee and colleagues [1] analyzes the ability to deliver adjuvant chemotherapy in patients after lobectomy, comparing the thoracoscopic with the open approach. Patients who underwent thoracoscopic lobectomy were better able to tolerate adjuvant chemotherapy, as measured by the percentage of patients who received 2011 by The Society of Thoracic Surgeons /$36.00 Published by Elsevier Inc doi: /j.athoracsur
Thoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationLong-term respiratory function recovery in patients with stage I lung cancer receiving video-assisted thoracic surgery versus thoracotomy
Original Article Long-term respiratory function recovery in patients with stage I lung cancer receiving video-assisted thoracic surgery versus thoracotomy Tae Yun Park 1,2, Young Sik Park 2 1 Division
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationNumber of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival
Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationThoracoscopic Lobectomy: Technical Aspects in Years of Progress
Thoracoscopic Lobectomy: Technical Aspects in 2015 16 Years of Progress 8 th Masters of Minimally Invasive Thoracic Surgery Orlando September 25, 2015 Thomas A. D Amico MD Gary Hock Professor of Surgery
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationLung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
More informationMinimally Invasive Esophagectomy
Minimally Invasive Esophagectomy M A R K B E R R Y, M D A S S O C I AT E P R O F E S S O R D E PA R T M E N T OF C A R D I O T H O R A C I C S U R G E R Y S TA N F O R D U N I V E R S I T Y S E P T E M
More informationESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationVATS after induction therapy: Effective and Beneficial Tips on Strategy
VATS after induction therapy: Effective and Beneficial Tips on Strategy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J. Swanson, M.D. Professor of
More informationAdjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer
Review Article Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer Robert Pirker Department of Medicine I, Medical University of Vienna, Vienna, Austria Correspondence
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationRobotic lobectomy: revolution or evolution?
Editorial Robotic lobectomy: revolution or evolution? Jules Lin Section of Thoracic Surgery, Department of Surgery, University of Michigan Medical Center, Ann Arbor, Michigan, USA Correspondence to: Jules
More informationPrognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer
Ann Thorac Cardiovasc Surg 2011; 17: 58 62 Case Report Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer Motoki Yano, MD, Hidefumi Sasaki, MD, Satoru Moriyama, MD, Osamu Kawano MD, Yu
More informationClinical Commissioning Policy Proposition: Robotic assisted lung resection for primary lung cancer
Clinical Commissioning Policy Proposition: Robotic assisted lung resection for primary lung cancer Reference: NHS England B10X03/01 Information Reader Box (IRB) to be inserted on inside front cover for
More informationStage IB Nonsmall Cell Lung Cancers: Are They All the Same?
ORIGINAL ARTICLES: GENERAL THORACIC GENERAL THORACIC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationROBOT SURGEY AND MINIMALLY INVASIVE TREATMENT FOR LUNG CANCER
ROBOT SURGEY AND MINIMALLY INVASIVE TREATMENT FOR LUNG CANCER Giulia Veronesi European Institute of Oncology Milan Lucerne, Samo 24 th - 25 th January, 2014 DIAGNOSTIC REVOLUTION FOR LUNG CANCER - Imaging
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationParenchyma-sparing lung resections are a potential therapeutic
Lung Segmentectomy for Patients with Peripheral T1 Lesions Bryan A. Whitson, MD, Rafael S. Andrade, MD, and Michael A. Maddaus, MD Parenchyma-sparing lung resections are a potential therapeutic option
More informationHistory of Surgery for Lung Cancer
Welcome to Master Class for Oncologists Session 1: 7:30 AM - 8:15 AM San Francisco, CA October 23, 2009 Innovations in The Surgical Treatment of Lung Cancer Speaker: Scott J. Swanson, MD 2 Presenter Disclosure
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationFacing Surgery for Lung Cancer? Learn about minimally invasive da Vinci Surgery
Facing Surgery for Lung Cancer? Learn about minimally invasive da Vinci Surgery Treatments & Surgery Options: The treatment and surgical options for the most common lung cancer, non-small cell lung cancer,
More informationUniportal video-assisted thoracoscopic surgery following neoadjuvant chemotherapy for locally-advanced lung cancer
Yang and Zhai Journal of Cardiothoracic Surgery (2018) 13:33 https://doi.org/10.1186/s13019-018-0714-9 RESEARCH ARTICLE Open Access Uniportal video-assisted thoracoscopic surgery following neoadjuvant
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationAccepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
More informationVATS Lobectomy Tecnica triportale
VATS Lobectomy Tecnica triportale Prof. Giuseppe Marulli UOC Chirurgia Toracica Policlinico Universitario di Padova VATS LOBECTOMY: FIRST EXPERIENCES CLINICAL MAIN CONCERNS Morbidity/mortality rates comparable
More informationThree-arm robot-assisted thoracoscopic surgery for locally advanced N2 non-small cell lung cancer
Surgical Technique Three-arm robot-assisted thoracoscopic surgery for locally advanced N2 non-small cell lung cancer Xinghua Cheng, Chongwu Li, Jia Huang, Peiji Lu, Qingquan Luo Shanghai Chest Hospital,
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationFeasibility of four-arm robotic lobectomy as solo surgery in patients with clinical stage I lung cancer
Original Article Feasibility of four-arm robotic lobectomy as solo surgery in patients with clinical stage I lung cancer Seong Yong Park, Jee Won Suh, Kyoung Sik Narm, Chang Young Lee, Jin Gu Lee, Hyo
More informationThe Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy
The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene M. Correa, PhD, Ritsuko Komaki, MD, Joe Y. Chang,
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationIs uniportal thoracoscopic surgery a feasible approach for advanced stages of non-small cell lung cancer?
Original rticle Is uniportal thoracoscopic surgery a feasible approach for advanced stages of non-small cell lung cancer? Diego Gonzalez-Rivas 1,2, Eva Fieira 1, Maria Delgado 1, Lucía Mendez 1, Ricardo
More informationUniportal Video-Assisted Thoracoscopic Lobectomy: Two Years of Experience
Uniportal Video-Assisted Thoracoscopic Lobectomy: Two Years of Experience Diego Gonzalez-Rivas, MD, Marina Paradela, MD, Ricardo Fernandez, MD, Maria Delgado, MD, Eva Fieira, MD, Lucía Mendez, MD, Carlos
More informationLearning Curve of a Young Surgeon s Video-assisted Thoracic Surgery Lobectomy during His First Year Experience in Newly Established Institution
Korean J Thorac Cardiovasc Surg 2012;45:166-170 ISSN: 2233-601X (Print) ISSN: 2093-6516 (Online) Clinical Research http://dx.doi.org/10.5090/kjtcs.2012.45.3.166 Learning Curve of a Young Surgeon s Video-assisted
More informationMastering Thoracoscopic Upper Lobectomy
Mastering Thoracoscopic Upper Lobectomy Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery, Duke University Medical
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationLymph node metastasis is the most important prognostic
ORIGINAL ARTICLE Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and III-Tubulin Between Primary Non-small Cell Lung Cancer
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More informationLung cancer is the leading cause of cancer-related death in
ORIGINAL ARTICLE Use of Adjuvant Chemotherapy in Non-small Cell Lung Cancer in Routine Practice Christophe Massard, MD,* Pierre Tran Ba Loc, MD, Vincent Haddad, MS, Jean-Pierre Pignon, MD, Philippe Girard,
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationCheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda
Original Article Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy for patients with clinical stage IA non-small cell lung cancer: a propensity score
More informationUniportal video-assisted thoracoscopic lobectomy: an alternative to conventional thoracoscopic lobectomy in lung cancer surgery?
Interactive CardioVascular and Thoracic Surgery Advance Access published March 3, 2015 Interactive CardioVascular and Thoracic Surgery (2015) 1 7 doi:10.1093/icvts/ivv034 THORACIC Cite this article as:
More informationLong-Term Survival After Video-Assisted Thoracic Surgery Lobectomy for Primary Lung Cancer
Long-Term Survival After Video-Assisted Thoracic Surgery Lobectomy for Primary Lung Cancer Kazumichi Yamamoto, MD, Akihiro Ohsumi, MD, Fumitsugu Kojima, MD, Naoko Imanishi, MD, Katsunari Matsuoka, MD,
More informationVideo-Assisted Thoracic Surgery (VATS) Lobectomy: the Evidence Base
SCIENTIFIC PAPER Video-Assisted Thoracic Surgery (VATS) Lobectomy: the Evidence Base Naveed Alam, MD, Raja M. Flores, MD ABSTRACT Background: Video-assisted thoracic surgery (VATS) lobectomy provides a
More informationSystemic therapy in early stage NSCLC. Disclosures
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationRole of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer
ONCOLOGY LETTERS 4: 1349-1353, 2012 Role of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer MENG WANG 1,2, JING ZHAO 3, YAN-JUN SU 1,2, XIAO-LIANG ZHAO 1,2 and CHANG-LI WANG 1,2
More informationReasons for conversion during VATS lobectomy: what happens with increased experience
Review Article on Thoracic Surgery Page 1 of 5 Reasons for conversion during VATS lobectomy: what happens with increased experience Dario Amore, Davide Di Natale, Roberto Scaramuzzi, Carlo Curcio Division
More informationPneumonectomy After Induction Rx: Is it Safe?
Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction
More informationDetermining the Optimal Surgical Approach to Esophageal Cancer
Determining the Optimal Surgical Approach to Esophageal Cancer Amit Bhargava, MD Attending Thoracic Surgeon Department of Cardiovascular and Thoracic Surgery Open Esophagectomy versus Minimally Invasive
More informationTreatment of Non-small Cell Lung Cancer Stage I and Stage II* ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER: ACCP GUIDELINES Treatment of Non-small Cell Lung Cancer Stage I and Stage II* ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Walter J.
More informationClinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis
Original Article Clinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis Seok Joo 1, Dong Kwan Kim 2, Hee Je Sim
More informationLong-Term Outcome and Cost-Effectiveness of Complete Versus Assisted Video-Assisted Thoracic Surgery for Non-Small Cell Lung Cancer
2011;104:162 168 Long-Term Outcome and Cost-Effectiveness of Complete Versus Assisted Video-Assisted Thoracic Surgery for Non-Small Cell Lung Cancer JIANXING HE, MD, PhD, FACS, 1,2 * WENLONG SHAO, MD,
More informationProper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer
Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Özcan Birim, MD, A. Pieter Kappetein, MD, PhD, Tom Goorden, MD, Rob J. van Klaveren, MD,
More informationPost-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
More informationstate of the art standard of care for resectable NSCLC surgical approach for resectable NSCLC
state of the art standard of care for resectable NSCLC surgical approach for resectable NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie
More informationSingle Technology Appraisal (STA)
Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response
More informationPoor Prognostic Factors in Patients With Stage IB Non-small Cell Lung Cancer According to the Seventh Edition TNM Classification
CHEST Original Research Poor Prognostic Factors in Patients With Stage IB Non-small Cell Lung Cancer According to the Seventh Edition TNM Classification LUNG CANCER Ryo Maeda, MD ; Junji Yoshida, MD, PhD
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationVideo-assisted thoracoscopic (VATS) lobectomy has
Robot-Assisted Lobectomy for Early-Stage Lung Cancer: Report of 100 Consecutive Cases Farid Gharagozloo, MD, Marc Margolis, MD, Barbara Tempesta, MS, CRNP, Eric Strother, LSA, and Farzad Najam, MD Washington
More informationRobotic assisted VATS lobectomy for loco-regionally advanced non-small cell lung cancer
Surgical Technique Page 1 of 5 Robotic assisted VATS lobectomy for loco-regionally advanced non-small cell lung cancer Simon R. Turner, M. Jawad Latif, Bernard J. Park Thoracic Surgery Service, Memorial
More informationAdjuvant chemotherapy of completely resected early stage nonsmall cell lung cancer (NSCLC)
Review Article Adjuvant chemotherapy of completely resected early stage nonsmall cell lung cancer (NSCLC) Ying Liang 1, Heather A. Wakelee 2 1 Department of Medical Oncology, Cancer Center, Sun Yat-sen
More informationACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD
ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD 7-12-12 ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy
More informationState of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy?
ESMO Preceptorship Programme NSCLC Singapore 13 14 dec 2016 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationPerioperative outcomes and lymph node assessment after induction therapy in patients with clinical N1 or N2 non-small cell lung cancer
Original Article Perioperative outcomes and lymph node assessment after induction therapy in patients with clinical N1 or N2 non-small cell lung cancer Jessica Glover 1, Frank O. Velez-Cubian 2, Kavian
More informationIs there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer?
Original Article Is there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer? Yutao Liu 1*, Xiaoyu Zhai 1*, Junling Li 1, Zhiwen Li 2, Di Ma
More informationSURGICAL TECHNIQUE. Radical treatment for left upper-lobe cancer via complete VATS. Jun Liu, Fei Cui, Shu-Ben Li. Introduction
SURGICAL TECHNIQUE Radical treatment for left upper-lobe cancer via complete VATS Jun Liu, Fei Cui, Shu-Ben Li The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China ABSTRACT KEYWORDS
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More informationAccepted Manuscript. Adjuvant Chemotherapy in Stage I Lung Cancer: Is More Better? Chuong D. Hoang, MD
Accepted Manuscript Adjuvant Chemotherapy in Stage I Lung Cancer: Is More Better? Chuong D. Hoang, MD PII: S0022-5223(18)31821-X DOI: 10.1016/j.jtcvs.2018.06.069 Reference: YMTC 13198 To appear in: The
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationNSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy
Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local
More informationACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD
ACOSOG Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy Govindan, M.D. Carolyn Reed, MD
More informationControversies in management of squamous esophageal cancer
2015.06.12 12.47.48 Page 4(1) IS-1 Controversies in management of squamous esophageal cancer C S Pramesh Thoracic Surgery, Department of Surgical Oncology, Tata Memorial Centre, India In Asia, squamous
More informationOBJECTIVES. Solitary Solid Spiculated Nodule. What would you do next? Case Based Discussion: State of the Art Management of Lung Nodules.
Organ Imaging : September 25 2015 OBJECTIVES Case Based Discussion: State of the Art Management of Lung Nodules Dr. Elsie T. Nguyen Dr. Kazuhiro Yasufuku 1. To review guidelines for follow up and management
More informationLung cancer is a prevalent health problem worldwide. It is the leading cause
Prognostic factors in resected stage I non small cell lung cancer with a diameter of 3 cm or less: Visceral pleural invasion did not influence overall and disease-free survival Jung-Jyh Hung, MD, a,b Chien-Ying
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationProton therapy for post-operative radiation therapy of non-small cell lung cancer
Mini-Review Proton therapy for post-operative radiation therapy of non-small cell lung cancer Annemarie Fernandes Shepherd Memorial Sloan Kettering Cancer Center, Basking Ridge, NJ, USA Correspondence
More information11/21/ M with LUL Mass Case Presentation / Round Table Discussion. Multiple-choice question What stage is this tumor?
MS 62M with LUL Mass Case Presentation / Round Table Discussion Dr. Jasleen Kukreja and Johannes Kratz Department of Thoracic Surgery University of California, San Francisco 62M, presented to clinic 6/2009
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationCANCER TREATMENT REGIMENS
CANCER TREATMENT S Lung Cancer The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation
More informationSmall cell lung cancer (SCLC), which represents 20%
ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,
More informationLung Cancer in Octogenarians: Factors Affecting Morbidity and Mortality After Pulmonary Resection
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More informationAshleigh Clark 1, Jessica Ozdirik 2, Christopher Cao 1,2. Introduction
Review Article Page 1 of 5 Thoracotomy, video-assisted thoracoscopic surgery and robotic video-assisted thoracoscopic surgery: does literature provide an argument for any approach? Ashleigh Clark 1, Jessica
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationSupplementary Material
1 Supplementary Material 3 Tumour Biol. 4 5 6 VCP Gene Variation Predicts Outcome of Advanced Non-Small-Cell Lung Cancer Platinum-Based Chemotherapy 7 8 9 10 Running head: VCP variation predicts NSCLC
More informationRobotic-assisted thoracoscopic sleeve lobectomy for locally advanced lung cancer
Original Article Robotic-assisted thoracoscopic sleeve lobectomy for locally advanced lung cancer Mong-Wei Lin, Shuenn-Wen Kuo, Shun-Mao Yang, Jang-Ming Lee Department of Surgery, National Taiwan University
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More information